# PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

> **NCT07472140** · PHASE2,PHASE3 · RECRUITING · sponsor: **N.N. Alexandrov National Cancer Centre** · enrollment: 120 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancers
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** PARP inhibitor + Bevacizumab
- **DRUG:** PARP inhibitor

## Key facts

- **NCT ID:** NCT07472140
- **Lead sponsor:** N.N. Alexandrov National Cancer Centre
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2033-06-30
- **Final completion:** 2033-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472140, "PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07472140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*